|Mr. Jeffrey Lucero Riley MBA||CEO, Pres & Director||1.03M||N/A||54|
|Mr. Steven A. Shallcross CPA||CFO, Treasurer & Sec.||601.18k||N/A||56|
|Dr. Michael Kaleko M.D., Ph.D.||Sr. VP of R&D||N/A||N/A||N/A|
|Dr. Joseph A. Sliman M.D., MPH||Chief Medical Officer||N/A||N/A||44|
|Dr. Raymond D. Stapleton Jr., Ph.D.||Sr. VP of Manufacturing||N/A||N/A||N/A|
Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates in Phase III development include SYN-010, which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase) that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), antibiotic-associated diarrhea (AAD), and the emergence of antimicrobial resistance (AMR). The company is also developing SYN-007 and SYN-006 for the prevention of CDI and AAD; SYN-005, a monoclonal antibody therapy for the prevention and treatment of pertussis; SYN-200 for the treatment of phenylketonuria; and SYN-020, an oral dosage form of intestinal alkaline phosphatase. It has collaboration agreements with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.
Synthetic Biologics, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 2; Compensation: 9.